References
- Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache35(7), 387–396 (1995).
- Lipton RB, Stewart WF, Diamond S et al. Prevalence and burden of migraine in the United States: data from the American Migraine II Study. Headache41(7), 646–657 (2001).
- MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. Headache43(1), 19–26 (2003).
- Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Curr. Treat. Options Neurol.13(1), 1–14 (2011).
- Luthringer R, Djupesland PG, Sheldrake CD et al. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J. Pharm. Pharmacol.61(9), 1219–1228 (2009).
- Djupesland PG, Docekal P; Czech Migraine Investigators Group. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomized, placebo-controlled study. Cephalalgia30(8), 933–942 (2010).
- Djupesland PG, Skretting A, Windern M et al. Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope116(3), 466–472 (2006).
- Siegel SJ, O’Neill C, Dube LM et al. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan succinate. Headache47(5), 753 (2007).
- Pierce M, Marbury T, O’Neill C et al. Zelrix: a novel transdermal formulation of sumatriptan. Headache49(6), 817–825 (2009).
- Goldstein J, Pugach N, Smith TR. Acute anti-migraine efficacy and tolerability of Zelrix, a novel iontophoretic transdermal patch of sumatriptan. Cephalalgia29(Suppl. 1), 20 (2009).
- Pierce MW. Transdermal delivery of sumatriptan for the treatment of acute migraine. Neurotherapeutics7(2), 159–163 (2010).
- Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology45(3 Pt 1), 577–584 (1995).
- Shrewsbury SB, Cook RO, Taylor G et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. Headache48(3), 355–367 (2008).
- Aurora SK, Rozen TD, Kori SH et al. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache49(6), 826–837 (2009).
- Silberstein SD, Kori SH, Tepper SJ et al. Efficacy and tolerability of MAP0004, a novel orally inhaled therapy, in treating acute migraine. Cephalalgia1(Suppl. 1), 12 (2009).